Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).
ESMO Open · 2025-Dec · PMID 41337859
OS
Figure 3 Association of RadSig1 with OS landmarked at 10-week follow-up. Each signature’s output was an individualized estimation and a continuous value ranging from 0 to 1 (from most to least favorable estimated OS). The analysis of median OS in our study revealed distinct outcomes across quartiles (log-rank, P < 0.0001). The median OS for the overall cohort was 13.5 months (95% CI 6.1-20.9 months), with the first quartile reaching 17.8 months (95% CI 7.1-28.5 months), the second quartile at 15.0 months (95% CI 10.0-20.1 months), the third quartile at 5.6 months (95% CI 3.0-8.2 months), and the fourth quartile exhibiting a markedly lower median OS of 1.3 months (95% CI 0.0-3.5 months). CI, confidence interval; OS, overall survival.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 4 | 2026-07-18T19:41:23+00:00 |